Literature DB >> 10761451

von Willebrand factor is the most reliable immunohistochemical marker for megakaryocytes of myelodysplastic syndrome and chronic myeloproliferative disorders.

S S Chuang1, Y C Jung, C Y Li, Y C Yung.   

Abstract

To find the best immunohistochemical marker for megakaryocytes in normal marrow, myelodysplastic syndrome (MDS), and chronic myeloproliferative disorders (CMPD), 57 marrow biopsy specimens were studied semiquantitatively with immunohistochemical methods using a panel of 7 antibodies. The staining intensity was graded 0 to 3 for scoring 100 consecutive megakaryocytes in each stained section. The final score for each stain was the sum of these 100 megakaryocytes individually multiplied by their corresponding grade. In normal marrow (11 cases), the average scores for antivon Willebrand factor (vWF) and Ulex europaeus agglutinin-1 (UEA-1) were 177.1 and 195.1, respectively. The scores for the other 5 markers, including anti-platelet-derived growth factor-BB, 2 anti-transforming growth factor-beta 3, anti-CD61, and anti-CD79a ranged from 96.1 to 124.1. In MDS (27 cases), the scores were 200.8 (vWF), 152.6 (UEA-1), and 28.7 to 98.5 (others). In CMPD (19 cases), the scores were 220.5 (vWF), 179.2 (UAE-1), and 64.8 to 101.2 (others). These results show that vWF and UEA-1 are good immunohistochemical markers for megakaryocytes in normal marrow, and vWF is the best marker in MDS and CMPD. For routine practice, vWF is the most reliable marker for identifying atypical megakaryocytes, especially in the cases of 5q-syndrome and agnogenic myeloid metaplasia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10761451     DOI: 10.1309/9Q6D-GXHU-N1K9-T6BH

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  4 in total

1.  Reduced ribosomal protein gene dosage and p53 activation in low-risk myelodysplastic syndrome.

Authors:  Kelly A McGowan; Wendy W Pang; Rashmi Bhardwaj; Marcelina G Perez; John V Pluvinage; Bertil E Glader; Reem Malek; Susan M Mendrysa; Irving L Weissman; Christopher Y Park; Gregory S Barsh
Journal:  Blood       Date:  2011-07-25       Impact factor: 22.113

Review 2.  The role of morphology, cytochemistry and immunohistochemistry in the diagnosis of chronic myeloproliferative diseases.

Authors:  Chin-Yang Li
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

3.  Tissue Morphology and Antigenicity in Mouse and Rat Tibia: Comparing 12 Different Decalcification Conditions.

Authors:  Kristofor Bogoevski; Anna Woloszyk; Keith Blackwood; Maria A Woodruff; Vaida Glatt
Journal:  J Histochem Cytochem       Date:  2019-05-15       Impact factor: 2.479

4.  A novel mechanism of thrombocytopenia by PS exposure through TMEM16F in sphingomyelin synthase 1 deficiency.

Authors:  Yoritaka Fujii; Makoto Taniguchi; Shingo Nagaya; Yoshibumi Ueda; Chieko Hashizume; Ken Watanabe; Hiroyuki Takeya; Takeo Kosaka; Toshiro Okazaki
Journal:  Blood Adv       Date:  2021-10-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.